Download our poster presented at Discovery on Target (DOT) 2024, where we explore innovative approaches to identifying selective small molecule inhibitors for oncogenic mutant forms of Kinase ‘X’. Learn how Logica’s AI-driven DNA-encoded library (DEL) screening and cutting-edge biochemical assays are shaping the future of precision medicine and targeted cancer therapies.
Poster Overview
This poster showcases Logica’s advanced workflow for Mechanism of Inhibition (MOI) studies, highlighting a medicinal chemistry campaign designed to enhance the selectivity of inhibitors targeting mutant Kinase ‘X’ without affecting the wild-type form. By using allosteric binding sites and non-ATP competitive molecules, the study aims to improve potency while minimizing side effects.
What You’ll Learn
- The innovative DEL screening strategy used to identify selective inhibitors for Kinase ‘X’
- How mechanism of inhibition (MOI) studies at earlier drug discovery stages can drive better decision-making
- Key findings from the medicinal chemistry program that led to a 10-fold improvement in potency for selective kinase inhibitors
Poster Authors: Dan Still, Siobhan Ryan, David Whalley, & Christine Edwards (Charles River Laboratories); Kristopher King, Kelly McCarthy, & Kyle Denton (Valo Health)
Download the Poster
Fill out the form below to access cutting-edge kinase inhibitor research that could redefine your approach to small molecule drug discovery.